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developed a partial infarct, and 25 % developed a complete 
infarct. Successful recanalization significantly increased the 
chance to develop no or only partial infarct compared with a 
complete infarction (p = 0.003, p = 0.013).
Conclusions Thrombectomy of small vessels with pRE-
set LITE is feasible with good recanalization and reason-
able safety margins. Successful recanalization significantly 
reduces the risk of infarction in the dependent territory. 
The impact on the overall clinical outcome remains to be 
determined.
Keywords Stroke · Treatment ·  
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Introduction
Endovascular recanalization of large vessel occlusion with 
stent retrievers was recently established as an evidence-based 
therapy for acute stroke. Five randomized trials clearly dem-
onstrated that endovascular treatment in combination with 
standard medical measures is superior to medical treatment 
alone [1–5]. Target vessels within these trials were largely 
confined to the most proximal segments of brain-supplying 
arteries, which are most likely to cause severe stroke syn-
dromes in case of an acute occlusion and are least likely to 
be injured by mechanical manipulation. This is in line with 
the approval of most stent retrievers starting from a vessel 
diameter of 2 mm and up to 9 mm for the largest available 
device. Embolic occlusion of vessels smaller than 2 mm is 
frequently encountered during mechanical thrombectomy 
and may reflect either extension of a thrombus of a larger 
vessel into a smaller branch, primary occlusion of a small 
branch, or spread of thrombus material due to fragmentation 
during the procedure. If branches supplying eloquent brain 
  W. Kurre
wiebke.kurre@gmx.de; w.kurre@klinikum-stuttgart.de
1 Neurologische Klinik, Klinikum Stuttgart,  
Kriegsbergstrasse 60, 70174 Stuttgart, Germany
2 Medizinische Fakultät der Universität Duisburg-Essen, 
Hufelandstrasse 55, 45122 Essen, Germany
Abstract
Purpose Few devices are approved for thrombectomy of 
distal vessel branches, and clinical experience is limited. 
Here we report our experience with pREset LITE for throm-
bectomy of small intracranial vessels.
Methods From an institutional database we selected con-
secutive patients treated with pREset LITE for an occlu-
sion of small (≤ 2 mm), intracranial target vessels. Recan-
alization success was measured by applying the modified 
Thrombolysis In Cerebral Infarction (mTICI) score. To as-
sess safety, we recorded device-related procedural events 
and potentially device-related hemorrhages on follow-up 
imaging. Infarcts in the dependent territory served as a mea-
sure for efficacy.
Results Of 536 patients treated between August 2013 and 
March 2015, 76 met the inclusion criteria. pREset LITE was 
used in 90 branches with an average diameter of 1.6 mm 
(1.3–2.0 mm). An mTICI score ≥ 2b was achieved in 70.0 %. 
Procedural events consisted of 5.6 % significant vasospasm, 
2.2 % suspected dissections, 2.2 % downstream emboli, 
and 1.1 % self-limiting extravasations. On posttreatment 
imaging 2.2 % parenchymal hemorrhages type I (PHI) and 
13.3 % focal subarachnoid hemorrhage (SAH) were poten-
tially device related, but all of these events remained as-
ymptomatic. After successful recanalization, 33.3 % devel-
oped no ischemia in the dependent territory while 41.7 % 
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nasogastric tube. A body weight adapted bolus of eptifi-
batide was applied intravenously to bridge the period of 
resorption and activation of the P2Y12 receptor antagonist.
Procedures were routinely performed under general 
anesthesia by four experienced interventional neuroradiolo-
gists. In the anterior circulation an 8 French guide catheter 
(Guider SoftipTM XF, Boston Scientific, Plymouth, MN, 
USA) was used in combination with an intermediate cath-
eter (5max ACETM, Penumbra Inc., Alameda, CA, USA; 
Navien A+ 0.58TM, Medtronic, Dublin, Ireland). A balloon 
guide catheter (CelloTM 8F, Medtronic, Dublin, Ireland) was 
rarely chosen. Vascular access in the posterior circulation in 
large-lumen vertebral arteries was gained with an 8 F guide 
catheter (Guider SoftipTM XF) in combination with an inter-
mediate catheter (5max ACETM, Navien A+ 0.58TM). In small 
lumen vertebral arteries a 6 F guide catheter (Envoy XBTM, 
Codman and Shurtleff, Raynham, MA, USA) without an 
intermediate catheter was chosen. In case of difficult trans-
femoral access a large lumen intermediate catheter (Navien 
A+ 0.72TM, Medtronic, Dublin, Ireland) was introduced 
transbrachially without a guide catheter. Access vessel ste-
noses or occlusions were treated by stent angioplasty pref-
erentially prior to the intracranial recanalization procedure.
The occluded target vessel was catheterized with a 0.021- 
or 0.025-inch inner lumen microcatheter (Trevo® pro 18, 
Stryker, Mountain View, CA, USA; PX Velocity, Penumbra 
Inc., Alameda, CA, USA) guided by a 0.014-inch guide wire 
(Synchro2 ®, Stryker Neurovascular, Freemont, CA, USA). 
For catheterization of small caliber branches either the same 
microcatheter or a 0.017-inch microcatheter (EchelonTM 
10 or 14, Medtronic, Dublin, Ireland) was chosen. The 
stent retriever (pREsetTM/pREset LITETM, phenox GmbH, 
Bochum, Germany; SolitaireTM, Medtronic, Dublin, Ireland; 
EmbotrapTM, Neuravi, Galway, Ireland; 3D Separator, Pen-
umbra Inc., Alameda, CA, USA) was deployed beyond the 
assumed occlusion site. After 5-min incubation and intra-
arterial injection of 0.5–1 mg glycerol trinitrate the inter-
mediate catheter was navigated as close to the thrombus as 
possible. During recanalization of M2 segments the inter-
mediate catheter was positioned in the distal M1 segment 
during recanalization of anterior cerebral artery branches in 
the distal ICA and during recanalization of posterior cere-
bral arteries in the distal basilar artery. The thrombectomy 
device was withdrawn under continuous aspiration of the 
intermediate catheter. Gentle pulling of the intermediate 
catheter prevented uncontrolled forward movement during 
thrombectomy. Arterial hypotension was pharmacologically 
compensated by intravenous injection of cafedrine hydro-
chloride/theodrenaline hydrochloride. In case of persistent 
occlusion or incomplete recanalization, thrombectomy was 
repeated with the same or another device. If recanalization 
was not achieved after several thrombectomy maneuvers, 
the procedure was either aborted or continued using angio-
tissue are affected, recanalization is desirable. A few new 
generation stent retrievers with either reduced radial force 
or small crossing profile or both are now approved for the 
treatment of vessels with a diameter of > 1.5 mm. Up to now 
the knowledge about safety and efficacy of thrombectomy 
in small vessels is limited. Here we report our experience 
with pREset LITE (phenox GmbH, Bochum, Germany) for 
the treatment of vessels ≤ 2 mm.
Methods
Patient Selection
From a prospectively maintained institutional database we 
selected consecutive patients treated with pREset LITE in 
target vessels of ≤ 2 mm diameter between August 2013 and 
March 2015.
General Treatment Protocol
Patients referred for mechanical recanalization had a 
National Institute of Health Stroke Scale (NIHSS) ≥ 4 
caused by a major intracranial vessel occlusion of the ter-
minal carotid artery, the M1 or M2 segment of the middle 
cerebral artery, the basilar artery, or the P1 segment of the 
posterior cerebral artery. For definition of M2 we used the 
clinical approach considering the postbifurcational seg-
ment as the proximal part of the M2 branch. In multiple 
vessel occlusions we also treated anterior cerebral artery 
targets. Fluctuating clinical symptoms were the reason for 
treatment of patients with minor stroke severity at presen-
tation (NIHSS < 4). Treatment was performed within 8 h 
from symptom onset. Exceptions were made for patients 
beyond this time window in case of a mismatch between 
severity of symptoms and infarct size in imaging studies or 
fluctuating/progressive symptoms suggesting a salvageable 
penumbra supplied by collaterals. Patients with unknown 
time window were also selected based on this concept of 
clinical mismatch. Computer tomography (CT) or magnetic 
resonance imaging (MRI) was used as baseline imaging 
according to the local standards of the referring hospital. 
Large-vessel occlusion was confirmed by CT angiography 
(CTA) or magnetic resonance angiography (MRA).
Intravenous Alteplast was given prior to the endovascular 
procedure in a subset of patients according to the decision of 
the referring neurologist. Patients with a suspected stenosis 
or dissection received a loading dose of 500 mg acetylsali-
cylic acid and 180 mg ticagrelor or 600 mg clopidogrel but 
no Alteplast to reduce the risk of hemorrhage. If a patient 
did not receive preloading but stenting had to be performed, 
500 mg acetylsalicylic acid was applied intravenously fol-
lowed by 180 mg ticagrelor or 600 mg clopidogrel via a 
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follow-up imaging. Hemorrhages were divided into paren-
chymal hemorrhages type I and II (PHI, PHII) according to 
the “European Cooperative Acute Stroke Study” and sub-
arachnoid hemorrhage (SAH) [6]. A hemorrhage was classi-
fied as possibly device related if it was anatomically related 
to the target branch and no other cause was identifiable. A 
device-related adverse event or hemorrhage was regarded 
as symptomatic if the NIHSS increased by ≥ 4 points, and 
the adverse event or hemorrhage was the most likely cause 
for the clinical deterioration. Follow-up imaging was also 
evaluated regarding new infarcts in the territory of the target 
branch and findings categorized into no, partial, and com-
plete infarction. If more than one follow-up examination 
existed, all were screened for hemorrhage and infarction.
Statistics
Fisher’s exact test was used to assess the dependency 
between recanalization of the target branch and infarction 
on follow-up imaging, in general, as well as the influence 
of the recanalization status on the extent of infarction and 
the influence of occlusion type on the extent of infarction. A 
p-value < 0.05 was defined as statistically significant. Odds 
ratio (OR) and 95 % confidence intervals (95 % CI) were 
calculated for the influence of the recanalization status on 
the extent of infarction. All analyses were performed with 
STATA/IC 11.2 for Windows software (StataCorp, College 
Station, Texas).
Results
In the predefined period 536 patients were treated by endo-
vascular approach for acute ischemic stroke. Of these 
76 fulfilled the inclusion criteria. Baseline clinical data 
are summarized in Table 1. Primary targets for treatment 
were the terminal carotid artery (n = 17), the M1 segment 
of the middle cerebral artery (MCA) (n = 31), the M2 seg-
ment of the MCA (n = 20), the pericallosal (n = 2), basilar 
(n = 4), or posterior cerebral artery (n = 5). Three patients 
had two targets each. Distal access catheters were used in 
74 patients (97.4 %), in combination with a regular guide 
catheter in 69 (90.8 %) and in combination with a balloon 
guide in five (6.5 %). A regular guide catheter without distal 
access catheter was used in two patients (2.6 %). Successful 
recanalization was achieved in 69 targets (87.3 %). Cervical 
artery stenting was performed in 16 patients (21.1 %), and 9 
received intracranial stents (11.8 %). The mRS at 90 days is 
summarized in Fig. 1.
Recanalization of small caliber branches using pRE-
set LITE was attempted in 90 targets. Of the latter 63 
were primary occlusions, 14 were emboli into the already 
affected territory, 12 were emboli into a new territory, and 
plasty and/or stent deployment or intra-arterial thrombolysis 
as a rescue maneuver.
The decision to treat a small vessel branch during throm-
bectomy was made by the operator considering the severity 
and duration of clinical symptoms, collateral status, acces-
sibility of the branch, and eloquence of the dependent brain 
tissue. pREset LITE was chosen as a device in anatomical 
situations in which according to the judgment of the opera-
tor the use of a regular 4-mm stent retriever appeared to 
harbor an increased risk considering the vessel diameter, its 
angulation, and the retraction pathway.
After thrombectomy the patient was kept sedated and 
ventilated until the next day to allow for precise blood pres-
sure management tolerating a maximum peak systolic value 
of 130 mm Hg.
Follow-up imaging was done at least 24–48 h posttreat-
ment using either CT or MRI. Further imaging was per-
formed depending on clinical demands.
pREset LITE Device Design and Assessment
pREset LITE was developed for recanalization of small 
caliber intracranial vessels (> 1.5 mm) and is officially 
approved for this purpose in Europe (Conformité Europée-
nne). The device is available with a diameter of 3 and 4 mm. 
Working length is 20 mm for both versions. Both devices 
are designed to fit inside a 0.0165-inch microcatheter. The 
radial force of pREset LITE is significantly lower compared 
with the regular pREset while cell configuration and over-
all device design are similar. According to the manufacturer 
the radial force of pREset LITE 4–20 in a 2-mm vessel is 
approximately 30 % and that of pREset LITE 3–20 65 % 
lower compared with a regular pREset 4–20.
Data Assessment
For all patients we assessed baseline clinical data including 
age, etiology of stroke, common vascular risk factors, time 
from symptom onset to treatment, NIHSS at presentation, 
primary target vessels for treatment, and the rate of suc-
cessful recanalization (modified thrombolysis in cerebral 
infarction score (mTICI) 2b or 3). We also reported whether 
cervical or intracranial artery stenting was performed during 
the procedure. Ninety-day modified Ranking Scale (mRS) 
scores were collected for assessment of clinical outcome.
To evaluate the performance of pREset LITE we identi-
fied the small caliber target branch the device was used in. 
Feasibility was defined as successful deployment of pRE-
set LITE at the intended location, and recanalization suc-
cess was measured applying the mTICI score focused on 
the target branch. Successful recanalization was defined 
as mTICI ≥ 2b. Safety aspects were addressed by report-
ing device-associated adverse events and hemorrhages on 
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high friction. In the first patient intra-arterial thrombolysis 
was performed without recanalization of the target vessel; 
in the second case thrombectomy with pREset LITE 3–20 
was successful. In 15 of 27 branches with unsuccessful 
recanalization after thrombectomy with pREset LITE, fur-
ther treatment was attempted. Seven branches were success-
fully recanalized by permanent implantation of a stent. Two 
of the stents were implanted assuming an underlying dis-
section possibly induced by pREset LITE. Stent retrievers 
with higher radial force were used in seven targets. In three 
patients pREset 4–20 was applied leading to recanalization 
in two. One patient was successfully treated with pREset 
6–30. Recanalization with Solitaire 4–20 was attempted in 
two targets of which one was successfully recanalized. In 
the last patient recanalization attempts with pREset 4–20, 
1 was undetermined. A typical case is presented in Fig. 2. 
Location of the target branches, average target vessel 
diameters, recanalization results after thrombectomy with 
pREset LITE, and the number of passes are summarized in 
Table 2. Successful recanalization was achieved in 63 tar-
gets (70.0 %) with an average of 1.3 passes (0–4). More than 
two passes were performed in six targets (6.7 %). pREset 
LITE 4–20 was attempted in 57, pREset LITE 3–20 in 25, 
and both devices in 8 targets. On two occasions microcath-
eter passage of the occlusion was possible but vessel tor-
tuosity precluded placement of pREset LITE 4–20 due to 
Table 1 Baseline clinical data of patients treated with pREset LITE
Number of patients (n) 76
Average age (years (range)) 71 (36–93)
Female (n(%)) 34 (44.7 %)
Average NIHSS at presentation (range)a 14 (0–27)
Average time from onset to treatment (min 
(range))
255 (112–486)
Unknown time of clinical onset (n = (%)) 17 (22.4 %)
Progressive or fluctuating symptoms (n = (%)) 4 (5.3 %)
Treatment more than 8 h after symptom onset 5 (6.6 %)
Stroke etiology (n(%))
Cardiac embolism 46 (60.5 %)
Extra- or intracranial large artery atherosclerosis 14 (18.4 %)
Embolic stroke of unknown etiology 7 (9.2 %)
Rare causesb 9 (11.8 %)
Cardiovascular risk factors (n(%))
Atrial fibrillation 50 (65.8 %)
Diabetes mellitus 18 (23.7 %)
Hypercholesterolemia 22 (28.9 %)
Hypertension 58 (76.3 %)
Current smoker 13 (17.1 %)
Coronary artery disease 19 (25.0 %)
Peripheral artery disease 8 (10.5 %)
aAvailable for n = 68 (five patients were referred intubated and in 
three patients the NIHSS was not assessed)
bIncludes dissection, endocarditis, paraneoplastic disease, stent 
thrombosis, and iatrogenic stroke during surgical or endovascular 
procedures
Fig. 1 Distribution of mRS 
scores at 90 days (data missing 
for two patients)
 
Table 2 Target branches for thrombectomy with pREset LITE, av-
erage target vessel diameter, recanalization results, and number of 
thrombectomy passes performed with pREset LITE
Target branches for pREset LITE (n ) 90
M1 segment of the MCA 1 (1.1 %)
Temporal MCA branch 1 (1.1 %)
M2 segment of the MCA 61 (67.8 %)
A2 segment of the anterior cerebral artery 4 (4.4 %)
Pericallosal artery 10 (11.1 %)
Callosomarginal artery 2 (2.2 %)
Frontopolar artery 1 (1.1 %)
Basilar artery 1 (1.1 %)
P1 segment of the posterior cerebral artery 2 (2.2 %)
P2 segment of the posterior cerebral artery 7 (7.8 %)
Average vessel diameter 1.6 mm (1.3–2 mm)
Recanalization results after thrombectomy 
with pREset LITE
mTICI 0 21 (23.3 %)
mTICI 1 1 (1.1 %)
mTICI 2a 5 (5.6 %)
mTICI 2b 19 (21.1 %)
mTICI 3 44 (48.9 %)
Average number of passes 1.3 (0–4)
mTICI modified thrombolysis in cerebral infarction
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pered compared with the first catheterization. Both were 
young patients with a cervical artery dissection as an under-
lying cause of stroke. One self-limiting extravasation was 
observed, and in five patients severe vasospasm occurred, 
which resolved after intra-arterial infusion of vasodilators. 
In two patients the spread of thrombus material occurred, 
one was a downstream embolus and one was an embolus 
into an adjacent branch. We did not observe a clinical dete-
Solitaire 5–20, and Separator 3D remained unsuccessful. In 
one patient intra-arterial Alteplast was infused but the vessel 
remained occluded.
Possible or definite device-related adverse events con-
sisted of two suspected dissections treated by permanent 
implantation of a stent. The diagnosis of dissection was 
anticipated because the vessel remained occluded after 
thrombectomy and reentry of the occluded vessel was ham-
Fig. 2 The patient was referred 
for the treatment of a right M1 
occlusion after failure of intra-
venous thrombolysis. After the 
first pass partial recanalization 
was achieved, but an embolic 
occlusion of the angular artery 
occurred (a, b). A pREset LITE 
4–20 was deployed starting  
in the M3 segment with the  
proximal landing zone in M2  
(c, d, arrow = distal markers, open 
arrow = proximal marker).  
A TICI 3 result was achieved 
after thrombectomy (e, f)
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Details regarding recanalization success, type of occlusion, 
and imaging outcome are summarized in Table 3.
Discussion
Triggered by the positive results of the recently published 
prospective randomized trials, mechanical thrombectomy 
will become an integral part of stroke therapy and will con-
tribute to improved clinical outcome of patients. However, 
the trials providing evidence for the effectiveness of endo-
vascular stroke therapy mainly focused on proximal large 
artery occlusions of either the terminal carotid artery or the 
M1 segment of the MCA. Despite the fact that some trials 
allowed M2 occlusions to be included, only a few patients 
with an occlusion beyond M1 were randomized. This was 
possibly driven by the assumption that peripheral artery 
occlusions cause less severe clinical syndromes and respond 
well to intravenous thrombolysis. Earlier studies proved a 
relative safety of M2 compared with M1 thrombectomy 
even with the MERCI device, but still some safety concerns 
remain [7]. Several curves have to be overcome to access a 
peripheral target and will be stretched during device retrac-
tion. Thus, thrombectomy in small caliber peripheral ves-
sels may harbor an increased procedural risk. The failure to 
prove a clinical benefit of early M2 reperfusion in a pooled 
analysis of the PROACT II, IMS, and IMSII study may 
have supported the reluctance to include these patients into 
a prospective trial [8].
On the other hand distal vessel occlusions may lead 
to serious and permanent morbidity. Despite the fact that 
patients with an M2 occlusion have a better prognosis 
compared with patients with a more proximal occlusion, 
unfavorable outcome can be expected in up to 45 % if left 
rioration related to these events. Thus, they presumably did 
not cause additional harm.
Follow-up imaging was available for 74 patients with 87 
targets. Per patient it revealed 6 PHII (8.1 %), 5 PHI (6.8 %), 
and 15 SAH (20.2 %), of which only one was a diffuse SAH. 
Of these hemorrhages 2 PHI and 12 focal SAH were ana-
tomically related to the pREset LITE target and thus clas-
sified as potentially device-related (2.2 % PHI and 13.8 % 
focal SAH per target). None of these hemorrhages had an 
impact on the clinical outcome.
Regarding ischemic lesions in the dependent territory, 
no infarct was seen in 25 (28.7 %), partial infarcts in 33 
(37.9 %), and complete infarcts in 29 (33.3 %) occasions. 
In successfully recanalized patients the rate of no, par-
tial, and complete infarction was 33.3, 45.8, and 25.8 %, 
respectively. We found a significant relationship between 
successful recanalization and infarcts on follow-up imag-
ing (p = 0.002). Successful recanalization significantly 
increased the chance of no compared with complete infarc-
tion (p = 0.003, OR 14.7 (95 %CI 1.4–155)) and partial com-
pared with complete infarction (p = 0.013, OR 6.1 (95 % CI 
1.4–27.6)) but not of none compared with partial infarction 
(p = 0.627, OR 2.4 (95 % CI 0.2–25.4)) (Fig. 3). Compar-
ing imaging outcome between occlusion types the chance to 
develop no infarct was highest in patients with emboli into 
a new territory compared with emboli in the same territory 
or primary occlusion, but the difference was not statistically 
significant, neither for the whole cohort nor for successfully 
recanalized patients only (p = 0.163, p = 0.438) (Fig. 4). 
Fig. 4 Infarcts on follow-up imaging after successful recanalization 
of embolic occlusions in a new territory, in the same territory, and pri-
mary occlusions. There was a statistically not significant trend for less 
infarct after successful recanalization of occlusions in a new territory 
(p = 0.438)
 
Fig. 3 New infarcts in the territory of the target branch depend on 
recanalization success (p = 0.002). With successful recanalization the 
chance of no infarct is significantly higher compared with a complete 
infarct (p = 0.003, OR 14.7 (95 % CI 1.4–155)) and of a partial infarct 
compared with a complete infarct (p = 0.013, OR 6.1 (95 % CI 1.4–
27.6)) but not of no compared with a partial infarct (p = 0.627, OR 2.4 
(95 % CI 0.2–25.4))
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untreated [9]. Intravenous thrombolysis improves outcome, 
but still up to 30 % of patients will die or be dependent at 
90 days [10, 11]. Similar considerations hold true for pos-
terior cerebral artery occlusions, which can be associated 
with severe somatosensory and behavioral as well as cogni-
tive deficits [12]. Even after intravenous thrombolysis the 
rate of unfavorable outcome after posterior cerebral artery 
occlusion may be as high as 40 % [13]. These data support 
the search for more effective treatment strategies for distal 
vessel occlusions.
Occlusion of distal vessels may also be encountered 
while treating more proximal targets. Emboli to multiple 
territories or thrombus extension to small branches can be 
a primary finding. In addition, thrombus fragmentation and 
embolization to distal branches or new territories are known 
side effects of mechanical recanalization. Emboli into new 
territories can be expected in 0.7–11 % of recanalization 
procedures depending on the technique applied [14–16]. 
Recanalization attempts seem reasonable if eloquent brain 
tissue is jeopardized and recanalization techniques with a 
good safety profile are available.
Recently some multi- and mono-centric studies emerged 
addressing thrombectomy of M2 branches as well as anterior 
cerebral artery occlusions in one series [17–20]. Treatment 
in these studies was performed with regular stent retriev-
ers and demonstrated good feasibility and safety. Successful 
recanalization of M2 was associated with improved clinical 
outcome and smaller infarct size in one investigation [17]. 
However, in some distal branch occlusions, treatment with 
already available devices may be considered to be poten-
tially harmful due to the small diameter of the affected ves-
sel, location of the occlusion in a curved vessel segment, or 
retraction pathway. Retrievers with a reduced radial force 
and diameter fitting through small caliber microcatheters 
may increase the spectrum of potentially treatable vessel 
occlusions.
pREset LITE 4–20 and 3–20 were designed and approved 
to meet these demands. In this manuscript we report our 
clinical experience with the two devices regarding recanali-















TICI ≥ 2b pRE-
set LITE
63 62 24 
(38.7)
22 (35.5) 16 
(25.8)
TICI < 2b pRE-
set LITE





10 10 0 (0.0) 8 (80) 2 (20)
All successfully 
recanalized
73 72 24 
(33.3)








TICI ≥ 2b pRE-
set LITE
39 39 14 
(35.9)
14 (35.9) 11 (28.2)
TICI < 2b pRE-
set LITE





10 10 0 (0.0) 9 (90.0) 1 (10.0)
All successfully 
recanalized
49 49 14 
(28.6)




14 12 0 (0.0) 1 (8.3) 11 (91.7)
Emboli to same 
territory
14 13
TICI ≥ 2b pRE-
set LITE
11 10 3 (30.0) 4 (30.8) 3 (30.0)
TICI < 2b pRE-
set LITE







11 10 3 (30.0) 4 (30.8) 3 (30.0)
All not success-
fully recanalized
3 3 1 (33.3) 2 (66.6) 0 (0.0)
Emboli to new 
territory
12 12
TICI ≥ 2b pRE-
set LITE
12 12 7 (58.3) 3 (25.0) 2 (16.7)













Not classified 1 1
TICI ≥ 2b pRE-
set LITE
1 1 0 (0.0) 1 (100.0) 0 (0.0)
Table 3 Extent of infarcts in the small vessel territory depending on 
the recanalization status for all patients and subdivided into primary 

























Table 3 (continued) 
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distal vessel branches is slightly higher, but both intracra-
nial dissections occurred in patients with a cervical artery 
dissection and may reflect a higher vulnerability due to an 
underlying vessel wall disease. In addition, the diagnosis 
of dissection was only suspected based on the difficulty to 
reenter the target branch and was not proven by the typi-
cal aspect of an intimal flap. A different explanation of this 
phenomenon (e.g., change of the mechanical properties of 
the thrombus due to the previous recanalization attempt) 
cannot be excluded. Alternatively, dissections may be 
underreported in the literature and “hiding” in the rate of 
unsuccessful recanalization attempts.
With the treatment of distal branches the risk of ves-
sel perforation and intraprocedural hemorrhage could be 
increased. Device-related intraprocedural contrast extrava-
sation was only observed once; it was self-limiting and with-
out impact on the final outcome. Analysis of posttreatment 
imaging revealed potentially device-related PHI or SAH in 
2.2 and 13.3 %. Although none of the latter altered the clini-
cal course, the frequency of SAH was in the upper range 
compared with literature references. SAH was reported to 
occur in 0.9–16.2 % in stent-retriever studies and was below 
10 % in most publications [1–5, 12, 15, 23]. Studies explic-
itly analyzing the frequency and impact of SAH or con-
trast extravasation after thrombectomy performed imaging 
immediately or a few hours after treatment, and SAH may 
disappear at later time points [22, 24]. Since our patients 
did not routinely receive immediate posttreatment imaging 
studies, the frequency of SAH may even be underestimated. 
The authors reporting the highest rate of SAH of 16.2 % 
found an association with rescue angioplasty, which cannot 
serve as an explanation for the SAH we found after throm-
bectomy of small branches. Therefore, the hemorrhage is 
most likely attributable to the distal location of the target 
vessel. Stretching and rupture of small perforating branches 
may serve as an explanation for these angiographically 
occult bleedings. Predictors of procedure-related SAH were 
analyzed in detail after treatment with the MERCI device, 
and the authors found distal MCA occlusion to be an inde-
pendent predictor together with hypertension, rescue angio-
plasty, and intraprocedural perforation [25]. In the same 
study SAH was without impact on clinical outcome unless 
extensive or accompanied by severe parenchymal hema-
toma. The benign course of SAH due to angiographically 
occult bleeding was also confirmed in a retrospective case 
control study investigating this phenomenon after stent-
retriever thrombectomy [26]. In summary, up to now there 
is no evidence of clinical impairment due to focal SAH after 
mechanical thrombectomy, but some uncertainty remains 
since larger studies are still lacking.
Statistical analysis revealed a significant relationship 
between recanalization and infarcts in the dependent terri-
tory. With successful recanalization the chance to develop 
situations in which the operator felt treatment with regular 
devices to be associated with an increased risk. In our analy-
sis we included target branches with a diameter equal to or 
less than 2 mm to focus on vessels, which cannot be treated 
with the well-described and established regular devices 
according to their specification.
Accessibility of peripheral branches was excellent, with 
only 2.2 % failed attempts and successful recanalization was 
achieved in 70.0 % of targets. For the treatment of proximal 
vessels with the regular pREset retriever a recanalization 
rate as high as 85 % was previously reported [21]. The small 
gap of successful recanalization between proximal and dis-
tal vessels could possibly be explained by the reluctance to 
act aggressively in small branches. This is underlined by the 
finding that more than two thrombectomy passes were rarely 
performed in a distal vessel. Recanalization rates reported in 
the recently published randomized trials addressing throm-
bectomy of large vessel occlusion ranged between 59 and 
88 %, which compares well with the 70 % achieved using 
pREset LITE in small vessels [1–5].
In terms of adverse events, significant vasospasm after 
retraction of the device was observed in 5.6 % but always 
resolved with the infusion of vasodilators and did not affect 
outcome in any case. Cerebral vasospasm occurs frequently 
after mechanical thrombectomy. A detailed analysis of 
procedural complications in the “Solitaire With the Inten-
tion For Thrombectomy” trial revealed some vasospasm in 
22.5 % after treatment with Solitaire but none was symp-
tomatic [12]. Haussen et al. reported their experience with 
Trevo XP 3 × 20 for the treatment of distal vessels and 
described relevant vasospasm in five of eight patients, and 
vasospasm always responded to vasodilators [22]. Thus, 
vasospasm after thrombectomy seems to be a benign phe-
nomenon even when treating smaller distal branches.
New emboli after thrombectomy with pREset LITE 
occurred only in two occasions. Theoretically, the risk 
of losing thrombus material using small, low radial force 
retrievers loaded with small thrombi could be increased dur-
ing the passage of larger proximal vessel segments. Since all 
patients in this series were treated with intermediate cath-
eters and distal aspiration, we did not observe emboli into 
new but only the same territory. Emboli into the same vascu-
lar territory have been described to occur in approximately 
4.4 % of cases [12]. Using this as a benchmark, a frequency 
of 2.2 % after treatment with pREset LITE is acceptable.
In two targets (2.2 %) dissection was suspected because 
the vessel remained occluded after thrombectomy and reen-
try seemed more difficult compared with prior catheteriza-
tions. No further thrombectomy was performed to avoid 
harm and, instead, self-expanding stents were permanently 
implanted to restore flow. Target vessel dissection is rarely 
reported after stent-retriever thrombectomy with a maxi-
mum rate of 1.5 % [15]. A rate of 2.2 % after treatment of 
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none or only a partial infarct was higher compared with the 
risk of complete infarction. Haussen et al. presented their 
initial experience using “Baby Trevo” in distal intracranial 
vessels [16]. The number of patients treated in their series 
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lized. Only one patient developed a complete infarct, four 
had a partial infarct, and three no infarct. Thus, the results 
were qualitatively comparable with the findings in our 
study. Due to the fact that the majority of patients developed 
at least a partial infarct, the authors considered the effec-
tiveness of thrombectomy in distal vessels to be unproven. 
Our study had a higher overall number of patients and a 
reasonable number of not successfully recanalized targets, 
which served as a comparator. Under these premises we 
were able to demonstrate that successful recanalization sig-
nificantly reduces the risk to develop a complete infarction 
in the dependent territory, and partial infarction also reflects 
at least partial treatment success. In addition, we found a 
trend for less infarcts in patients recanalized for emboli into 
a new territory. This finding is most likely attributable to the 
shorter occlusion time compared with patients with primary 
occlusions or emboli into the already affected territory.
Our study is limited by its retrospective nature and the 
fact that efficacy was proven by infarct occurrence and size, 
which served as a surrogate for clinical relevance. Fur-
ther studies to directly address the impact on clinical out-
come are warranted and could potentially be conducted in 
cases with primary isolated small branch occlusions. With 
embolic occlusions of more proximal vessels extending into 
smaller branches or secondary emboli, the impact of recana-
lization of a single branch on clinical outcome will be dif-
ficult to determine.
In summary, recanalization of distal branches is double-
edged with a good chance for successful recanalization and 
reduction of infarct size but an increased risk of focal SAH. 
Up to now there is no evidence for a relevant clinical impact 
of focal SAH after thrombectomy, but larger confirmative 
studies are lacking. With the remaining uncertainty, the most 
reasonable approach would be to confine thrombectomy of 
small vessels to branches supplying eloquent brain tissue, 
which increases the likelihood of a relevant clinical benefit.
Conclusion
Mechanical thrombectomy in small vessels with pREset 
LITE is feasible with good recanalization and reasonable 
safety margins. Successful recanalization of small branches 
significantly reduces the risk of infarction in the depen-
dent territory. The impact on the overall clinical outcome 
remains to be determined.
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